European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts).
Journal article
Perk J. et al, (2012), Eur Heart J, 33, 1635 - 1701
The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial.
Journal article
IST-3 collaborative group None. et al, (2012), Lancet, 379, 2352 - 2363
Prevention: Aspirin in primary prevention-good news and bad news
Journal article
Hennekens CH. and Baigent C., (2012), Nature Reviews Cardiology, 9, 262 - 263
New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper.
Journal article
De Caterina R. et al, (2012), J Am Coll Cardiol, 59, 1413 - 1425
Does intermittent pneumatic compression reduce the risk of post stroke deep vein thrombosis? The CLOTS 3 trial: study protocol for a randomized controlled trial.
Journal article
Dennis M. et al, (2012), Trials, 13
Prevention. Aspirin in primary prevention--good news and bad news.
Journal article
Hennekens CH. and Baigent C., (2012), Nat Rev Cardiol, 9, 262 - 263
Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy.
Journal article
Cholesterol Treatment Trialists' (CTT) Collaboration None. et al, (2012), PLoS One, 7
Antiplatelet agents for the treatment and prevention of atherothrombosis.
Journal article
Patrono C. et al, (2011), Eur Heart J, 32, 2922 - 2932
ACP Journal Club. Simvastatin plus ezetimibe reduced major atherosclerotic events in patients with chronic kidney disease.
Journal article
Laville M., (2011), Ann Intern Med, 155, JC5 - J02
Benefits of lowering cholesterol in chronic kidney disease - Authors' reply
Journal article
Baigent C. et al, (2011), The Lancet, 378, 1377 - 1378
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.
Journal article
Baigent C. et al, (2011), Lancet, 377, 2181 - 2192
Estimated glomerular filtration rate and the risk of major vascular events and all-cause mortality: a meta-analysis.
Journal article
Mafham M. et al, (2011), PLoS One, 6
Ezetimibe/simvastatin (vytorin) in heart and renal protection: The SHARP trial
Journal article
Alexander W. et al, (2011), P and T, 36
Prediction of ESRD and death among people with CKD: the Chronic Renal Impairment in Birmingham (CRIB) prospective cohort study.
Journal article
Landray MJ. et al, (2010), Am J Kidney Dis, 56, 1082 - 1094
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.
Journal article
Cholesterol Treatment Trialists’ (CTT) Collaboration None. et al, (2010), Lancet, 376, 1670 - 1681
Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease.
Journal article
Sharp Collaborative Group None., (2010), Am Heart J, 160, 785 - 794.e10
Cystatin C and risk of vascular and nonvascular mortality: a prospective cohort study of older men.
Journal article
Emberson JR. et al, (2010), J Intern Med, 268, 145 - 154
Antiplatelet therapy: aspirin for asymptomatic atherosclerosis?
Journal article
Patrono C. and Baigent C., (2010), Nat Rev Cardiol, 7, 306 - 307